|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
98,530,000 |
Market
Cap: |
18.88(M) |
Last
Volume: |
78,874 |
Avg
Vol: |
78,660 |
52
Week Range: |
$0.1916 - $0.1916 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s primary clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, which is in the pivotal Phase 3 VIITAL clinical trial. Co. is developing additional adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that Co. has licensed from University of North Carolina at Chapel Hill, and internal AAV vector research programs.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
42,758 |
62,758 |
88,758 |
104,627 |
Total Buy Value |
$154,036 |
$241,836 |
$346,094 |
$404,389 |
Total People Bought |
5 |
5 |
5 |
5 |
Total Buy Transactions |
5 |
6 |
9 |
12 |
Total Shares Sold |
0 |
7,084 |
41,479 |
98,636 |
Total Sell Value |
$0 |
$36,199 |
$179,159 |
$193,613 |
Total People Sold |
0 |
1 |
5 |
5 |
Total Sell Transactions |
0 |
1 |
8 |
13 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Amoroso Michael |
Director |
|
2023-06-14 |
4 |
A |
$4.62 |
$271,143 |
D/D |
58,689 |
115,130 |
|
- |
|
Wuchterl Donald A. |
Director |
|
2023-06-14 |
4 |
A |
$4.62 |
$271,143 |
D/D |
58,689 |
79,103 |
|
- |
|
Charles Faith L. |
Director |
|
2023-06-14 |
4 |
A |
$4.62 |
$271,143 |
D/D |
58,689 |
79,103 |
|
- |
|
Silverstein Christine Berni |
Director |
|
2023-06-14 |
4 |
A |
$4.62 |
$271,143 |
D/D |
58,689 |
94,214 |
|
- |
|
Alland Leila |
Director |
|
2023-06-14 |
4 |
A |
$4.62 |
$271,143 |
D/D |
58,689 |
79,103 |
|
- |
|
Alvino Mark |
Director |
|
2023-06-14 |
4 |
A |
$4.62 |
$271,143 |
D/D |
58,689 |
76,216 |
|
- |
|
Omalley Brendan M. |
SVP, General Counsel |
|
2023-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
90,902 |
184,421 |
|
- |
|
Vazzano Joseph Walter |
Chief Financial Officer |
|
2023-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
141,908 |
236,366 |
|
- |
|
Seshadri Vishwas |
Chief Executive Officer |
|
2023-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
336,826 |
501,731 |
|
- |
|
Seshadri Vishwas |
Chief Executive Officer |
|
2023-06-02 |
4 |
D |
$3.06 |
$2,531 |
D/D |
(827) |
164,905 |
|
- |
|
Alvino Mark |
Director |
|
2023-04-25 |
4 |
S |
$3.25 |
$2,883 |
D/D |
(887) |
17,527 |
|
- |
|
Omalley Brendan M. |
SVP, General Counsel |
|
2023-04-03 |
4 |
D |
$2.82 |
$293 |
D/D |
(104) |
93,519 |
|
- |
|
Amoroso Michael |
Director |
|
2023-03-20 |
4 |
S |
$2.33 |
$624 |
D/D |
(268) |
56,441 |
|
- |
|
Vazzano Joseph Walter |
Chief Financial Officer |
|
2023-03-15 |
4 |
D |
$2.60 |
$2,059 |
D/D |
(792) |
94,458 |
|
- |
|
Amoroso Michael |
Director |
|
2023-03-03 |
4 |
S |
$2.38 |
$2,385 |
D/D |
(1,002) |
56,709 |
|
- |
|
Omalley Brendan M. |
SVP, General Counsel |
|
2023-03-03 |
4 |
D |
$2.28 |
$472 |
D/D |
(207) |
93,623 |
|
- |
|
Omalley Brendan M. |
SVP, General Counsel |
|
2022-12-09 |
4 |
B |
$3.13 |
$18,370 |
D/D |
5,869 |
93,830 |
2.74 |
- |
|
Vazzano Joseph Walter |
Chief Financial Officer |
|
2022-11-18 |
4 |
B |
$4.00 |
$10,000 |
D/D |
2,500 |
95,250 |
2.74 |
- |
|
Omalley Brendan M. |
SVP, General Counsel |
|
2022-11-18 |
4 |
B |
$3.99 |
$29,925 |
D/D |
7,500 |
87,961 |
2.74 |
- |
|
Seshadri Vishwas |
Chief Executive Officer |
|
2022-10-17 |
4 |
D |
$4.30 |
$890 |
D/D |
(207) |
165,732 |
|
- |
|
Seshadri Vishwas |
Chief Executive Officer |
|
2022-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
155,200 |
165,939 |
|
- |
|
Vazzano Joseph Walter |
Chief Financial Officer |
|
2022-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
72,750 |
92,750 |
|
- |
|
Omalley Brendan M. |
SVP, General Counsel |
|
2022-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
72,750 |
80,461 |
|
- |
|
Alland Leila |
Director |
|
2022-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
20,414 |
|
- |
|
Mann Paul Elliot |
Director |
|
2022-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
16,907 |
|
- |
|
156 Records found
|
|
Page 2 of 7 |
|
|